[Video Profile] Interview with Michael Fons, VP Corporate Development at Inovio Biomedical

Inovio Biomedical’s electroporation technology uses brief, controlled electrical pulses to increase cellular uptake of gene expression in DNA-based treatments; this enhances the potency of DNA-based immunotherapies against cancers and infectious diseases.

Inovio has an extensive patent portfolio and line of devices and prototypes for electroporation-based DNA delivery. Interim clinical data from multiple studies has indicated safety and tolerability, heightened levels of antibody and T-cell immune responses, and durable local and systemic tumor responses – providing initial validation of electroporation’s ability to enhance DNA vaccine potency.

The company licenses its technology and works through collaboration. Current partners include:

• Merck (cancers)
• Wyeth (infectious diseases)
• HIV Vaccine Trial Network (HIV)
• National Cancer Institute (HIV)
• International AIDS Vaccine Initiative (HIV)
• Vical (metastatic melanoma)
• Moffitt Cancer Center (malignant melanoma)
• University of Southampton (prostate cancer)